Co-Authors
This is a "connection" page, showing publications co-authored by BEENU THAKRAL and SANAM LOGHAVI.
Connection Strength
1.882
-
Marked paraneoplastic leukemoid reaction in a patient with mesothelioma mimicking a myeloid neoplasm. Blood. 2020 02 06; 135(6):457.
Score: 0.717
-
Clonal evolution with acquisition of BCR-ABL1 in refractory acute myeloid leukemia post therapy with FLT3-inhibitor. Leuk Lymphoma. 2020 12; 61(13):3243-3246.
Score: 0.185
-
Prognostic impact of CD5 expression in diffuse large B-cell lymphoma in patients treated with rituximab-EPOCH. Eur J Haematol. 2017 Apr; 98(4):415-421.
Score: 0.145
-
The spectrum of hematologic neoplasms in patients with Li-Fraumeni syndrome. Am J Hematol. 2024 Dec; 99(12):2416-2419.
Score: 0.062
-
Optical genomic mapping is a helpful tool for detecting CCND1 rearrangements in CD5-negative small B-cell lymphoma: Two cases of leukemic non-nodal mantle cell lymphoma. Hum Pathol. 2024 02; 144:71-76.
Score: 0.059
-
Validation of a 12-color flow cytometry assay for acute myeloid leukemia minimal/measurable residual disease detection. Cytometry B Clin Cytom. 2023 Sep; 104(5):356-366.
Score: 0.057
-
DDX41 mutations in patients with non-myeloid hematologic neoplasms. Am J Hematol. 2023 08; 98(8):E193-E196.
Score: 0.056
-
Immune evasion phenotype is common in Richter transformation diffuse large B-cell lymphoma?variant. Virchows Arch. 2023 Jun; 482(6):1011-1019.
Score: 0.055
-
Immunophenotypic and genomic landscape of Richter transformation diffuse large B-cell lymphoma. Pathology. 2023 Jun; 55(4):514-524.
Score: 0.055
-
Value and pitfalls of assessing bone marrow morphologic findings to predict response in patients with myelofibrosis who undergo hematopoietic stem cell transplantation. Ann Diagn Pathol. 2022 Feb; 56:151860.
Score: 0.051
-
Myeloid neoplasms associated with t(3;12)(q26.2;p13) are clinically aggressive, show myelodysplasia, and frequently harbor chromosome 7 abnormalities. Mod Pathol. 2021 02; 34(2):300-313.
Score: 0.047
-
Emergence of BCR-ABL1 Fusion in AML Post-FLT3 Inhibitor-Based Therapy: A Potentially Targetable Mechanism of Resistance - A Case Series. Front Oncol. 2020; 10:588876.
Score: 0.047
-
Genomic and Immunophenotypic Landscape of Aggressive NK-Cell Leukemia. Am J Surg Pathol. 2020 09; 44(9):1235-1243.
Score: 0.047
-
Clinicopathological characterization of chronic lymphocytic leukemia with MYD88 mutations: L265P and non-L265P mutations are associated with different features. Blood Cancer J. 2020 08 26; 10(8):86.
Score: 0.047
-
RAS and TP53 can predict survival in adults with T-cell lymphoblastic leukemia treated with hyper-CVAD. Cancer Med. 2020 02; 9(3):849-858.
Score: 0.044
-
De novo CD5+ diffuse large B-cell lymphoma, NOS: clinical characteristics and outcomes in rituximab era. Leuk Lymphoma. 2020 02; 61(2):328-336.
Score: 0.044
-
Early T precursor acute lymphoblastic leukaemia/lymphoma shows differential immunophenotypic characteristics including frequent CD33 expression and in vitro response to targeted CD33 therapy. Br J Haematol. 2019 08; 186(4):538-548.
Score: 0.043
-
DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease. Am J Hematol. 2019 07; 94(7):757-766.
Score: 0.043
-
Chronic lymphoproliferative disorder of NK-cells: A single-institution review with emphasis on relative utility of multimodality diagnostic tools. Eur J Haematol. 2018 May; 100(5):444-454.
Score: 0.039
-
3q26/EVI1 rearrangement in myelodysplastic/myeloproliferative neoplasms: An early event associated with a poor prognosis. Leuk Res. 2018 02; 65:25-28.
Score: 0.039